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these issues from clinicians, patients, and the 
medical­device industry.
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The Author Replies: Because of their inherent 
complexity and widespread distribution, medical 
devices will occasionally malfunction, fail, or 
cause unexpected adverse events. It is challenging 
to predict the long­term performance of implant­
ed devices on the basis of bench testing or pre­
marketing clinical trials of short duration. Thus, 
for selected life­sustaining products, postmarket­
ing studies of sufficient size and duration must 
be required of manufacturers. Unfortunately, 
when questions first arose about the performance 
of the Medtronic Sprint Fidelis ICD lead, the 
available postmarketing data were insufficient 
to allow an accurate evaluation of the device’s 
performance. Over the ensuing months, tens of 
thousands of additional patients underwent im­
plantation of the lead, only to be notified of its 
recall a short time later.
There is no “deeper” problem than the un­
necessary exposure of patients to an underper­
forming permanently implanted medical device. 
Schultz outlines several important questions that 
must be answered in order to strengthen the 
device­approval and postmarketing­monitoring 
processes. In addition, technological advances 
such as remote, wireless device monitoring will, 
in some cases, facilitate collection of the needed 
performance data. More critical, however, is the 
need for a philosophical shift — from a medical­
device industry that primarily reacts to perfor­
mance failures to one that better anticipates them.
William H. Maisel, M.D., M.P.H.
Beth Israel Deaconess Medical Center 
Boston, MA 02215 
wmaisel@bidmc.harvard.edu
Mechanical Ventilation and Disuse Atrophy of the Diaphragm
To the Editor: In their article, Levine et al. 
(March 27 issue)1 conclude that atrophy of the hu­
man diaphragm occurs with mechanical ventila­
tion; this finding is consistent with our observa­
tion of atrophy of the diaphragm in a patient 
with a high spinal cord injury after 8 months of 
mechanical ventilation necessitated by the failure 
of one diaphragmatic pacemaker.2 In this pa­
tient, atrophy of the diaphragm was prevented in 
the hemidiaphragm connected to the function­
ing pacemaker by stimulating the pacemaker for 
only 30 minutes per day. Levine et al. speculate 
as to whether there are functional implications 
due to atrophy and whether strategies can be used 
to prevent atrophy. Our study addresses both of 
these questions. First, we found that atrophy was 
associated with profound reductions in tidal vol­
ume. Second, we found that stimulation of the 
phrenic nerve of the diaphragm for 30 minutes 
per day was sufficient to prevent atrophy. From 
our observations and those of Levine et al., one 
major question arises: Is the diaphragmatic acti­
vation associated with the forms of ventilation 
commonly used in the intensive care unit suffi­
cient to prevent disuse atrophy?
Dennis McCool, M.D.
Brown University 
Providence, RI 02860 
f_mccool@brown.edu
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To the Editor: Levine and colleagues confirm 
that in the absence of respiratory effort, mechan­
ical ventilation for as little as 1 day causes pro­
found atrophy of the diaphragm in adult humans, 
as it does in animals. Two decades ago, Knisely 
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and others1 reported dramatic evidence of venti­
lation­induced atrophy in infants. They compared 
autopsy material obtained from 13 infants who 
died after mechanical ventilation for at least 12 
days with that obtained from 26 infants who died 
after ventilation for 7 or days or less. Infants who 
were ventilated for a longer time had smaller dia­
phragm myofibers with histologic features of 
disuse atrophy, whereas strap and tongue mus­
cles appeared to be normal.2 To control for the 
nutritional and catabolic effects of illness, they 
assessed ratios of the cross­sectional areas of 
myofibers in the diaphragm to those of the strap 
or tongue muscle; both ratios were much lower 
among the subjects who were ventilated for a lon­
ger time. The rapidity of disuse atrophy reported 
by Levine and colleagues militates against pro­
longed total rest of the diaphragm in many adults 
as well as infants who are at risk for hypercapnic 
respiratory failure. 
Stephen H. Loring, M.D.
Beth Israel Deaconess Medical Center 
Boston, MA 02215 
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Knisely AS, Leal SM, Singer DB. Abnormalities of diaphrag­1. 
matic muscle in neonates with ventilated lungs. J Pediatr 1988; 
113:1074­7.
Schild K, Neusch C, Schönhofer B. Ventilator­induced dia­2. 
phragmatic dysfunction (VIDD). Pneumologie 2008;62:33­9.
To the Editor: Levine et al. report atrophy of the 
diaphragm muscle due to disuse in mechanically 
ventilated patients. Some issues have not been 
addressed appropriately. Brain death is associat­
ed with alteration in the mitochondrial function 
of skeletal muscle.1 This alteration may induce 
oxidative stress and subsequent protease activa­
tion resulting in myosin loss. Information about 
cellular energy failure in brain­dead patients may 
be provided by the ratio of lactate to pyruvate in 
plasma.1
Atrophy was investigated solely by measuring 
cross­sectional area. Levine and colleagues pro­
pose that a reduction in the cross­sectional area 
would predict an approximately 55% decrease in 
transdiaphragmatic pressure. However, a reduc­
tion in the cross­sectional area is not necessarily 
accompanied by reduced force generation.2 Con­
versely, we found that in patients with chronic 
obstructive pulmonary disease, the cross­section­
al area of the diaphragm was not different from 
that of controls, but single­fiber force generation 
was significantly reduced (by approximately 27%), 
which could be explained by a loss of myosin of 
approximately 29%.3 Thus, a prediction of re­
duction in force should not be based on cross­
sectional area, but rather on myosin content.3
Leo M.A. Heunks, M.D., Ph.D. 
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To the Editor: Levine and colleagues report on 
the effects of controlled mechanical ventilation 
on atrophy of the diaphragm. Although they cite 
other potential contributors to atrophy of the dia­
phragm (e.g., systemic inflammatory response 
syndrome and sepsis), they do not mention criti­
cal­illness polyneuropathy and myopathy and 
some of its risk factors, which also may lead to 
muscle atrophy and dysfunction of the diaphragm 
in these patients.1 Critical­illness polyneuropathy 
and myopathy is common, with a prevalence rang­
ing from 30 to 90%, and it may develop quickly 
after the onset of critical illness.2,3 Glycemic con­
trol may be an important strategy to mitigate 
critical­illness polyneuropathy and myopathy.4 In 
this study, the blood glucose level was signifi­
cantly higher in case patients versus controls 
(164 vs. 92 mg per deciliter, P<0.001), and only 
4 of 14 patients received insulin infusions. We 
posit a potential “two­hit” hypothesis, with an 
interaction between muscle inactivity and the 
early development of subclinical critical­illness 
polyneuropathy and myopathy, contributing to 
rapid muscle atrophy in critically ill patients. This 
hypothesis requires investigation in future stud­
ies. Increasing awareness of critical­illness poly­
neuropathy and myopathy and further research 
on reversible risk factors and potential therapies 
are needed to ameliorate weakness and diaphrag­
matic dysfunction in critically ill patients.2,5
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To the Editor: In the article by Levine and col­
leagues, controls were patients with good gen­
eral health and respiratory conditions that made 
them candidates for surgery. In the population of 
case subjects, four patients had been involved in 
motor vehicle accidents, which is a frequent cause 
of transient diaphragmatic paralysis and may 
cause long­term diaphragmatic eventration.1 In 
this case, a reduction in the diaphragmatic thick­
ness is expected, even without intubation.2 Four 
other patients had a history of drug or alcohol 
abuse. In these subjects, malnutrition is frequent 
and muscular impairment may involve the dia­
phragm.
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The Authors Reply: We agree with McCool and 
colleagues that the case report by Ayas et al.1 pro­
vides definitive evidence that unilateral phrenic­
nerve stimulation can prevent atrophy — as 
 assessed by ultrasound — in the ipsilateral hemi­
diaphragm. Therefore, bilateral phrenic­nerve 
stimulation may be useful in preventing atrophy 
of diaphragm fibers in patients with the combi­
nation of mechanical ventilation and diaphrag­
matic inactivity.
We also agree with Loring’s comments about 
the article by Knisely et al.2 Since their infant 
study subjects were not brain­dead, their observa­
tions provide support for our concept that brain 
death per se was not playing a major role in 
eliciting the myofiber atrophy observed in the 
diaphragms of our case subjects.
With regard to the comments by Heunks and 
Dekhuijzen, because of the lack of clinical and 
histologic data in the article by Sztark et al.,3 the 
mitochondrial dysfunction that they observed 
in the long peroneal muscle of their brain­dead 
organ­donor subjects may represent early changes 
associated with disuse in this limb muscle. Sec­
ond, myosin concentration was not measured in 
our diaphragm­biopsy specimens. Therefore, in 
our predictions of the maximum force­generat­
ing capacity of the diaphragm, we used measured 
cross­sectional areas, fiber­type proportions, and 
assumed normal specific force for the diaphragm­
biopsy specimens from both case subjects and 
controls. If the increased proteolysis observed in 
the diaphragms of the case subjects was accom­
panied by a decrease in myosin concentration, as 
compared with the diaphragms of the controls, 
the diaphragms of the case subjects would have 
shown a greater decrease in force­generating capac­
ity than that estimated in our article (i.e., a de­
crease in transdiaphragmatic pressure of >55%).
We agree with Fan and Needham that our 
case subjects had hyperglycemia, which is a risk 
factor for both critical­illness polyneuropathy and 
myopathy. Therefore, these conditions should be 
considered as possible causes of atrophy of dia­
phragm myofibers.4 The absence of necrosis and 
hypercellularity in the diaphragm­biopsy speci­
mens of our case subjects rules out the myopathy 
associated with the critical­illness polyneuropa­
thy and myopathy syndrome.5 Since we did not 
obtain sections of phrenic nerve, we cannot rule 
out a neural contribution to the atrophy of dia­
phragm fibers observed in our case subjects.
Regarding the concerns of Leo and Spaggiari, 
we do not believe that either trauma or malnutri­
tion played a role in eliciting the atrophy of dia­
phragm fibers in the case subjects because we 
excluded subjects with thoracoabdominal trauma 
from our case cohort and because these patients 
showed no signs of malnutrition; indeed, our 
data indicate that case and control subjects did 
not differ with respect to body­mass index.
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Cholesterol Gene Polymorphisms and Cardiovascular Events
To the Editor: Kathiresan and coworkers (March 
20 issue)1 find that a genotype score of nine, 
which was crafted from a combination of four 
single­nucleotide polymorphisms (SNPs) affecting 
high­density lipoprotein (HDL) cholesterol and 
five SNPs influencing low­density lipoprotein 
(LDL) cholesterol, is an independent risk factor 
for incident cardiovascular disease. Similarly, 
Willer et al. recently showed that 11 SNPs asso­
ciated with elevated LDL levels (most of which 
overlap with the genes included in the article by 
Kathiresan et al.) increase the risk of coronary 
artery disease.2 In contrast, the HDL­modulating 
SNPs reported by Willer et al. were not associated 
with the risk of coronary artery disease, although 
the HDL genes (cholesterol ester transfer protein 
[CETP], hepatic lipase [LIPC], lipoprotein lipase 
[LPL], and ATP­binding cassette subfamily A mem­
ber 1 [ABCA1]) were similar to those in the article 
by Kathiresan et al. By presenting a combined 
genotype score comprising distinct risk factors 
(i.e., HDL cholesterol and LDL cholesterol), Kathi­
resan et al. imply a predictive value of all of these 
SNPs; this is in clear contrast to the findings of 
Willer et al. Therefore, it would have been much 
more informative if the genotype scores for LDL 
and HDL genes had been reported separately, 
thereby allowing closer comparison with related 
studies.
Menno Vergeer, M.D. 
Karim El-Harchaoui, M.D. 
Erik S.G. Stroes, M.D.
Academic Medical Center 
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To the Editor: Genotype scores for risk predic­
tion are becoming increasingly popular; for in­
stance, the use of these scores has recently been 
proposed to predict cardiovascular disease and 
prostate cancer.1 The concept relies on two major 
assumptions. First, polymorphisms act indepen­
dently and additively on the risk of disease. Sec­
ond, their effects are approximately interchange­
able. The first assumption may be true, especially 
with regard to polymorphisms belonging to dif­
ferent biologic systems, but in practice it cannot 
be verified because current studies are under­
powered to do so. The second assumption is very 
questionable. For example, in the study reported 
by Kathiresan et al., the difference in the LDL 
cholesterol level between homozygote genotypes 
was 72 mg per deciliter for the proprotein con­
vertase subtilisin/kexin type 9 (PCSK9) polymor­
phism and 3 mg per deciliter for the LDL recep­
tor (LDLR) polymorphism. Similarly, in terms of 
risk, the score assumed that it is equivalent to 
carry HDL­lowering or LDL­increasing alleles, 
despite the fact that a score based only on HDL­
related genotypes led to a hazard ratio of 1.22, as 
compared with 1.11 for a score based on LDL­
related genotypes. Paradoxically, such scores 
take us away from the goal of individualized 
medicine.
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